About Samsung Bioepis
Samsung Bioepis is a company based in Incheon (South Korea) founded in 2012 was acquired by Samsung BioLogics in January 2022.. Samsung Bioepis operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Aclaris Therapeutics, among others.
- Headquarter Incheon, South Korea
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Samsung Bioepis Co., Ltd
-
Annual Revenue
$660.03 M (USD)2as on Dec 31, 2020
-
Net Profit
$117.14 M (USD)-48as on Dec 31, 2020
-
EBITDA
-
Latest Funding Round
- Investors
-
Employee Count
Employee Count
-
Acquired by
Samsung BioLogics
(Jan 27, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Samsung Bioepis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Samsung Bioepis
Samsung Bioepis has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Samsung BioLogics. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Contract development and manufacturing for biologics are provided.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Samsung Bioepis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Samsung Bioepis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Samsung Bioepis Comparisons
Competitors of Samsung Bioepis
Samsung Bioepis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Aclaris Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| domain | founded_year | HQ Location |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for the treatment of multiple disorders
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Samsung Bioepis
Frequently Asked Questions about Samsung Bioepis
When was Samsung Bioepis founded?
Samsung Bioepis was founded in 2012.
Where is Samsung Bioepis located?
Samsung Bioepis is headquartered in Incheon, South Korea.
What is the annual revenue of Samsung Bioepis?
Annual revenue of Samsung Bioepis is $660.03M as on Dec 31, 2020.
What does Samsung Bioepis do?
Developer of biosimilar drugs for the treatment of multiple diseases. It is a Joint venture formed by the collaboration of Samsung Biologics and Biogen to develop biosimilars of advanced biologics to treat conditions such as rheumatoid arthritis, psoriasis, and Crohns disease. Ontruzant is Samsung Bioepis first cancer biosimilar approved by the FDA. It provides biosimilar of Etanercept, Infliximab, Adalimumab, Trastuzumab, Bevacizumab, etc.
Who are the top competitors of Samsung Bioepis?
Samsung Bioepis's top competitors include Merck, Roivant Sciences and AbbVie.
Who are Samsung Bioepis's investors?
Samsung Bioepis has 1 investor. Key investors include Samsung BioLogics.